J Korean Orthop Assoc.
2023 Dec;58(6):485-490. 10.4055/jkoa.2023.58.6.485 .
Current Issues on Denosumab Use in Giant Cell Tumor of Bone
- Affiliations
-
- 1Department of Orthopaedic Surgery, St. Vincent's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea
- KMID: 2549823
- DOI: http://doi.org/10.4055/jkoa.2023.58.6.485
Abstract
- Since the FDA (U.S. Food and Drug Administration) approved the use of denosumab for giant cell tumor of bone in 2013, it has been applied preoperatively or in unresectable cases, and research on its effects, complications, and appropriate cessation has been active. Accordingly, the authors review the current issues of denosumab use in giant cell tumor of bone.
Keyword
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- Evaluation of Local Recurrence in Giant-Cell Tumor of Bone Treated by Neoadjuvant Denosumab
- Denosumab for Treatment of a Recurrent Cervical Giant-Cell Tumor
- Current Strategy of Chemotherapy for Bone Tumors
- Denosumab-Treated Giant Cell Tumor of the Bone Mimicking Low-Grade Central Osteosarcoma
- Giant Cell Tumor of the Temporal Bone
